Advertisement

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Related Videos

Gunter von Minckwitz, MD

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04, "The phase III ICE study: Adjuvant ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer."

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.

Charles E. Geyer, Jr, MD, FACP

Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial

Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.”

Harry D. Bear, MD, PhD

Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract PD2-1, “The effect on overall and disease-free survival by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40.”

Hope S. Rugo, MD

Hope S. Rugo, MD, on the Phase II FIRST Study

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Advertisement

Advertisement

Oct

12

Today In Oncology

Insurance and Cost Barriers to Oral Therapies for Blood Cancers

Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer

Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes

The Wistar Institute Names New President and Chief Executive Officer

Early Research Links Abdominal Obesity to Increased Lung Cancer Risk

Advertisement

© 2026 HSP News Service, L.L.C.